

Department: Market Operations

Segment: Capital Market Segment

Circular No.: MSE/TRD/8778/2020

Date: March 06, 2020

Change in Series - Bafna Pharmaceuticals Limited (BAFNAPH)

In continuation to the Exchange circular no. MSE/LIST/8724/2020 dated February 26, 2020 and pursuant SEBI guidelines vide circular reference no. SEBI/CIR/ISD/1/2010 dated September 2, 2010 and SEBI/CIR/MRD/DP/02/2012 dated January 20, 2012, trading members are hereby informed that Bafna Pharmaceuticals Limited (BAFNAPH) will be transferred from trade to trade segment (BE) to rolling segment (EQ) with effect from March 17, 2020.

For and on behalf of Metropolitan Stock Exchange of India Limited

Muhammed Khatri Asst. Vice President